Simvastatin: Review of updates on recent trends in pharmacokinetics, pharmacodynamics, drug-drug interaction, impurities and analytical methods

Current Pharmaceutical Analysis

Volumn 8, Issue 2, 2012, Pages 135-156

  Basniwal, Pawan Kumar ^a,b   Jain, Deepti ^a  

^a UNIVERSITY INSTITUTE OF TECHNOLOGY   (India)

^b Bharat Sewak Shiksha Samiti   (India)

Author keywords

Analytical methods; Impurities; Pharmacodynamics; Pharmacokinetics and simvastatin

Indexed keywords

AMIODARONE; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTIVIRUS AGENT; APOLIPOPROTEIN B; CALCIUM CHANNEL BLOCKING AGENT; CLARITHROMYCIN; COUMARIN DERIVATIVE; CYCLOSPORIN; DRUG METABOLITE; ERYTHROMYCIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; KETOCONAZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NEFAZODONE; PROTEINASE INHIBITOR; RIFAMPICIN; SIMVASTATIN; TRIACYLGLYCEROL; UNINDEXED DRUG; VERAPAMIL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALOPECIA; ANALYTIC METHOD; BLEEDING; BLURRED VISION; CARBON NUCLEAR MAGNETIC RESONANCE; CATARACT; COLORIMETRY; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG IMPURITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DYSGEUSIA; ELECTROCHEMISTRY; ELECTROSPRAY MASS SPECTROMETRY; ERECTILE DYSFUNCTION; FOOD DRUG INTERACTION; GRAPEFRUIT JUICE; HEADACHE; HIGH PERFORMANCE THIN LAYER CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; IMPOTENCE; INFRARED SPECTROSCOPY; INSOMNIA; ISCHEMIC HEART DISEASE; LIQUID CHROMATOGRAPHY ELECTROSPRAY IONIZATION TANDEM MASS SPECTROMETRY; MICELLAR ELECTROKINETIC CHROMATOGRAPHY; MOTOR NEUROPATHY; MYOPATHY; MYOSITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEINURIA; PROTHROMBIN TIME; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; RASH; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; RHABDOMYOLYSIS; SENSORY NEUROPATHY; SIDE EFFECT; SLEEP TIME; TANDEM MASS SPECTROMETRY; THROMBOCYTOPENIA; TITRIMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

CITRUS X PARADISI;

EID: 84861768394     PISSN: 15734129     EISSN: 1875676X     Source Type: Journal    
DOI: 10.2174/1573412911208020135     Document Type: Review

References (196)

1. th Edn, 2001, 971-1001.
2. Lacoste, L.; Lam, J.Y.T.; Hung, J.; Letchacovski, G.; Solymoss, C.B.; Waters, D. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation, 1995, 92, 3172-3177.
3. Pedersen, D.T.R. The Scandinavian simvastatin survival study group, randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet, 1994, 344(8934), 1383-1389.
4. Shepherd, J.; Cobbe, S.M.; Ford, I.; Isles, C.G.; Lorimer, A.R.; MacFarlane, P.W.; McKillop, J.H.; Packard, C.J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 1995, 333(20), 1301-1307.
5. Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; Davis, B.R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New Engl. J. Med. 1996, 335, 1001-1009.
6. Byington, R. P.; Jukema, J.W.; Salonen, J.T.; Pitt, B.; Bruschke, A.V.; Hoen, H.; Furberg, C.D.; Mancini, G.B.J. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program, Circulation, 1995, 92, 2419-2425.
7. The pravastatin multinational study group for cardiac risk patients, Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am. J. Cardiol., 1993, 72, 1031-1037.
8. Downs, J.R.; Clearfield, M.; Weis, S.; Whitney, E.; Shapiro, D.R.; Beere, P.A.; Langendorfer, A.; Stein, E.A.; Kruyer, W.; Gotto, J.A.M. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. J.A.M.A., 1998, 279(20), 1615-1622.
9. The long-term intervention with pravastatin in ischaemic disease (lipid) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 1998, 339, 1349-1357.
10. Recommendations of the European atherosclerosis society prepared by the international task force for prevention of coronary heart disease. Prevention of coronary heart disease: scientific background and new clinical guidelines. Nutr. Metab. Cardiovasc. Dis., 1992, 2, 113-156.
11. th Edn., 2005, 306-313.
12. nd Edn., 2006, 348-355.
13. th International Edn., 2004, 561-575.
14. Shen, P.M.; Shiao, M.S.; Chung, H.R.; Lee, K.R.; Chao, Y.S.; Hunt, V.M. Liquid chromatographic detrmination of 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors, J. Chin. Chem. Soc., 1996, 43, 451-457.
15. Sacks, F.M. The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am. J. Cardio., 2002, 90(2), 139-143.
16. Chong, P.H.; Seeger, J.D.; Franklin, C. Clinically relevant differences between the statins: implications for therapeutic selection. Am. J. Med., 2001, 111, 390-400.
17. Amarenco, P.; Lavallée, P.; Touboul, P.J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol., 2004, 3, 271-278.
18. Miao, X. S.; Metcalfe, C.D. Determination of cholesterol-lowering statin drugs in aqueous samples using liquid chromatographyelectrospray ionization tandem mass spectrometry. J. Chromatograp. A, 2003, 998, 133-141.
19. Ellison, D.K.; Moore, W.D.; Petts, C.R. Analytical profiles of drug substances and excipients, simvastatin. Academic Press, Amsterdam, 1993, 22, 359-430.
20. British Pharmacopoeia, Vol. II, Market Towers, 1 Line Elams Lane, London, SW8 5NQ. 2003, 1671-1673.
21. The United States Pharmacopoeia 26, The National Formulary 21, United States Pharmacopoeial Convention, INC. 12601, Twinbrook, Parkway, Rockville, MD-20852, 2007, 2, 1683-1684.
22. Alberts, A.W. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Cardiology, 1990, 77, 14-21.
23. Hoffman, W.F.; Alberts, A.W.; Anderson, P.S.; Chen, J.S.; Smith, R.L.; Willard, A.K. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors 4 Side chain ester derivatives of mevinolin. J. Med. Chem., 1986, 29, 849-852.
24. Kim, J.W.; Bae, H.; Lee, K.H.; Choi, K.D. A process for producing simvastatin. WO 0172734.
25. Dabak, K.; Adiyaman, M.; A new method for the synthesis of antihypercholesterolemic agent simvastatin. Helv. Chim. Acta, 2003, 86(3), 673-677.
26. Thaper, R.K.; Misra, S.; Kumar, Y.; Kumar, S.M.D.; Khanna, J.M. A cost-efficient synthesis of simvastatin via high-conversion methylation of an alkoxide ester enolate. Org. Process Res. Dev., 1999, 3(6), 476-479.
27. Askin, D.; Verhoeven, T.R.; Liu, T.M.H.; Shinkai, I. Synthesis of synvinolin: Extremely high conversion alkylation of an ester enolate. J. Org. Chem., 1991, 56, 4929-4932.
28. Doucette, G.; Tam, T.F.; Tao, Y.; Karimian, K.; Li, Y. Process to manufacture simvastatin and intermediates. WO 9965892.
29. Roy, J. Pharmaceutical ImpuritiesA mini-review, AAPS, Pharm. Sci. Tech., 2002, 3(2), 1-8.
30. Krstulovic, A.M.; Lee, C.R.; Firmin, S.; Jacquet G.; Van Dau C.N.; Tessier D.; LC.GC. Eur., 2002, 15, 31-41.
31. Wang, H.; Wu, Y.; Zhao, Z.; Fragmentation study of simvastatin and lovastatin using electrospray ionization tandem mass spectrometry. J. Mass Spectrom., 2001, 36, 58-70.
32. th Edn, A Wiley Interscience Publication, John Wiley & Sons, 2004, 408-1047.
33. Vuleti, M.; Cindri, M.; Koruznjak, J. D. Identification of unknown impurities in simvastatin substance and tablets by liquid chromatography/tandem mass spectrometry. J. Pharm. Biomed. Ana., 2005, 37, 715-721.
34. th Edn, 797-818.
35. Bertacche, V.; Milanese, A.; Nava, D.; Pini, E.; Stradi, R.; Structural elucidation of an unknown simvastatin by-product in industrial synthesis starting from lovastatin. J. Pharm. Biomed. Ana., 2007, 45, 642-647.
36. Mauro, V.F.; MacDonald, J.L. Simvastatin: a review of its pharmacology and clinical use. D.I.C.P. Ann. Pharmacother., 1991, 25, 257-264.
37. Plosker, G.L.; McTavish, D. Simvastatin: a reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs, 1995, 50, 334-363.
38. Riegger, G.; Abletshauser, C.; Ludwig, M.; Schwandt, P.; Widimsky, J.; Weidinger, G.; Welzel, D. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery dis ease during one year of treatment. Atherosclerosis, 1999, 144, 263-270.
39. Sever, P.S.; Dahlöf, B.; Poulter, N.R.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen S.E.; Kristinsson, A.; McInnes, G.T.; Mehlsen, J.; Nieminen, M.; O'Brien, E.; Ostergren, J. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes TrialLipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361, 1149-1158.
40. Miettinen, T. A.; Pyorala, K.; Olsson, A.G.; Musliner, T.A.; Cook, T.J.; Faergeman, O.; Berg, K.; Pedersen, T.; Kjekshus, J. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation, 1997, 96, 4211-4218.
41. Lewis, S.J.; Sacks, F.M.; Mitchell, J.S.; East, C.; Glasser, S.; Kell, S.; Letterer, R.; Limacher, M.; Moye, L.A.; Rouleau, J.L.; Pfeffer, M.A.; Braunwald, E. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J. Am. Coll. Cardiol., 1998, 32, 140-146.
42. Lewis, S.J.; Moye, L.A.; Sacks, F.M.; Johnstone, D.E.; Timmis, G.; Mitchell, J.; Limacher, M.; Kell, S.; Glasser, S.P.; Grant, J.; Davis, B.R.; Pfeffer, M.A.; Braunwald, E. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the cholesterol and recurrent events (CARE) trial. Ann. Intern. Med., 1998, 129, 681-689.
43. Hunt, D.; Young, P.; Simes, J.; Hague, W.; Mann, S.; Owensby, D.; Lane, G.; Tonkin, A. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the lipid trial. Ann. Intern. Med., 2001, 134, 931-940.
44. Heart Protection Study Collaborative Group. Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet, 2002, 360, 17-22.
45. Furberg, C.D.; Adams, H.P.; Applegate, W.B.; Byington, R.P.; Espeland, M.A.; Hartwell, T.; Hunninghake, D.B.; Lefkowitz, D.S.; Probstfield, J.; Riley, W.A. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation, 1994, 90, 1679-1687.
46. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet, 1994, 344, 633-638.
47. Herd, J.A.; Ballantyne, C.M.; Farmer, J.A.; Ferguson, J.J.; Jones, P.H.; West, M.S.; Gould, K.L.; Gotto, A.M.; Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations. Am. J. Cardiol., 1997, 80, 278-286.
48. Edwards, C.J.; Hart, D.J.; Spector, T.D.; Oral statins and increased bone-mineral density in postmenopausal women. Lancet, 2000, 355, 2218-2229.
49. Watanabe, S.; Fukumoto, S.; Takeuchi, Y.; Fujita, H.; Nakano, T.; Fujita, T. Effects of 1-year treatment with fluvastatin or pravastatin on bone. Am. J. Med., 2001, 110, 584-587.
50. Chan, K.A.; Andrade, S.E.; Boles, M.; Buist, D.S.; Chase, G.A.; Donahue, J.G.; Goodman, M.J.; Gurwitz, J.H.; LaCroix, A.Z.; Platt, R. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet, 2000, 355, 2185-2188.
51. Meier, C.R.; Schlienger, R.G.; Kraenzlin, M.E.; Schlegel, B.; Jick, H. HMG-CoA reductase inhibitors and the risk of fractures. J.A.M.A., 2000, 283, 3205-3210.
52. Wang, P.S.; Philip, S.; Wang, M.D.; Daniel, H.; Solomon, M.D.; Helen, M.; Jerry Avorn HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. J.A.M.A., 2000, 283, 3211-3216.
53. Reid, I.R.; Hague, W.; Emberson, J.; Baker, J.; Tonkin, A.; Hunt, D.; MacMahon, S.; Sharpe, N. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Lancet, 2001, 357, 509-512.
54. Van Staa, T.P.; Wegman, S.; de Vries, F.; Leufkens, B.; Cooper, C. Use of statins and risk of fractures. J.A.M.A., 2001, 285, 1850-1855.
55. LaCroix, A.Z.; Cauley, J.A.; Pettinger, M.; Hsia, J.; Bauer, D.C.; McGowan, J.; Chen, Z.; Lewis, C.E.; McNeeley, S.G.; Passaro, M.D.; Jackson, R.D. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann. Intern. Med., 2003, 139, 97-104.
56. Coons, J.C. Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management. Ann. Pharmacother., 2002, 36, 326-330.
57. Mauro, V.F. Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet., 1993, 24, 195-202.
58. Desager, J.P.; Horsmans, Y. Clinical pharmacokinetics of 3hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 1996, 31, 348-371.
59. Lennernäs, H.; Fager, G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin. Pharmacokinet. 1997, 32, 403-425.
60. Farmer, J.A.; Torre, A.G. Comparative tolerability of the HMGCoA reductase inhibitors. Drug Safety, 2000, 23, 197-213.
61. Davidson, M.H. Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. Drugs, 2001, 61, 197-206.
62. Pasternak, R.C.; Smith, S.C.; Bairey, M.C.; Noel, M.D.; Grundy, S.M.; Cleeman, J.I.; Lenfant, C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation, 2002, 106, 1024-1028.
63. Possamai, G.; Bovo, P.; Santonastaso, M. Thrombocytopenic purpura during therapy with simvastatin. Haematologica, 1992, 77, 357-358.
64. Schlienger, R.G.; Haefeli, W.E.; Jick, H.; Meier, C.R. Risk of cataract in patients treated with statins. Arch. Intern. Med., 2001, 161, 2021-2026.
65. Anonymous. Simvastatin and alopecia. Aust. Adverse Drug React. Bull., 1993, 12, 7-11.
66. Deslypere, J.P.; Delanghe, J.; Vermeulen, A. Proteinuria as complication of simvastatin treatment. Lancet, 1990, 336, 1453-1457.
67. Duits, N.; Bos, F.M. Depressive symptoms and cholesterollowering drugs. Lancet, 1993, 341(8837), 114-114.
68. Backes, J.M. Association of HMG-CoA reductase inhibitors with neuropathy. Ann. Pharmacother. 2003, 37, 274-278.
69. Anonymous. Paraesthesia and neuropathy with hypolipidaemic agents. Aust. Adverse Drug React. Bull., 1993, 12, 6-10.
70. Phan, T.; McLeod, J.G.; Pollard, J.D.; Peiris, O.; Rohan, A.; Halpern, J.P. Peripheral neuropathy associated with simvastatin. J. Neurol. Neurosurg. Psychiatry, 1995, 58, 625-628.
71. Jeppesen, U.; Gaist, D.; Smith, T.; Sindrup, S.H. Statins and peripheral neuropathy. Eur. J. Clin. Pharmacol., 1999, 54, 835-838.
72. Jackson, G. Simvastatin and impotence. B.M.J., 1997, 315, 31-31.
73. Australian Adverse Drug Reactions Advisory Committee. Simvastatin and adverse endocrine effects in men. Aust. Adverse Drug React. Bull., 1995, 14, 10-10.
74. Pedersen T.R.; Færgeman, O. Simvastatin seems unlikely to cause impotence. B.M.J., 1999, 318, 192.
75. Committee on Safety of Medicines/Medicines Control Agency. HMG CoA reductase inhibitors (statins) and myopathy. Current Problems, 2002, 28, 8-9.
76. Adverse Drug Reactions Advisory Committee (ADRAC). Fluvastatin and muscle disorders-a class effect. Aust. Adverse Drug React. Bull. 1997, 16, 3.
77. Ucar, M.; Mjörndal, T.; Dahlqvist, R. HMG-CoA reductase inhibitors and myotoxicity. Drug Safety, 2000, 22, 441-457.
78. Omar, M.A.; Wilson, J.P.; Cox, T.S. Rhabdomyolysis and HMGCoA reductase inhibitors. Ann. Pharmacother., 2001, 35, 1096-1107.
79. Omar, M.A.; Wilson, J.P. FDA adverse event reports on statinassociated rhabdomyolysis. Ann. Pharmacother., 2002, 36, 288-295.
80. Hargreaves, I.P.; Heales, S. Statins and myopathy. Lancet, 2002, 359, 711-712.
81. Barth, J.D.; Kruisbrink, O.A., Van Dijk, A.L. Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia. B.M.J., 1990, 301, 669.
82. Manson, J.M.; Freyssinges, C.; Ducrocq, M.B.; Stephenson, W.P. Postmarketing surveillance of lovastatin and simvastatin exposure during pregnancy. Reprod. Toxicol., 1996, 10, 439-446.
83. Kantola, T.; Kivistö, K.T.; Neuvonen, P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther., 1998, 64, 177-182.
84. Amsden, G.W.; Kuye, O.; Wei, G.C. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J. Clin. Pharmacol. 2002, 42, 444-449.
85. Lee, A.J.; Maddix, D.S. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann. Pharmacother., 2001, 35, 26-31.
86. Kyrklund, C.; Backman, J.T.; Kivistö, K.T.; Neuvonen, M.; Laitila, J.; Neuvonen, P.J. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 2000, 68, 592-597.
87. Yuen, S.L.S.; McGarity, B. Rhabdomyolysis secondary to interaction of fusidic acid and simvastatin. Med. J. Aust., 2003, 179, 172-172.
88. Williams, D.; Feely, J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin. Pharmacokinet. 2002, 41, 343-370.
89. Jacobson, R.H.; Wang, P.; Glueck, C.J. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. J.A.M.A., 1997, 277, 296-296.
90. Thompson, M.; Samuels, S. Rhabdomyolysis with simvastatin and nefazodone. Am. J. Psychiatry, 2002, 159, 1607-1607.
91. Neuvonen, P.J.; Kantola, T.; Kivisto, K.T. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin. Pharmacol. Ther., 1998, 63, 332-341.
92. Segaert, M.F.; De Soete, C.; Vandewiele, I.; Verbanck, J. Druginteraction-induced rhabdomyolysis. Nephrol. Dial. Transplant, 1996, 11, 1846-1847.
93. Shaukat, A.; Benekli, M.; Vladutiu, G.D.; Slack, J.L.; Wetzler, M.; Baer, M.R. Simvastatin-fluconazole causing rhabdomyolysis. Ann. Pharmacother., 2003, 37, 1032-1035.
94. Hsyu, P.H.; Schultz, S.; Lillibridge, J.H.; Lewis, R.H.; Kerr, B.M. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother., 2001, 45, 3445-3450.
95. Fichtenbaum, C.J.; Gerber, J.G.; Rosenkranz, S.L.; Segal, Y.; Aberg, J.A.; Blaschke, T.; Alston, B,.; Fang, F.; Kosel, B.; Aweeka, F. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS, 2002, 16, 569-577.
96. Cheng, C.H.; Miller, C.; Lowe, C.; Pearson, V.E.; Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am. J. Health-Syst Pharm., 2002, 59, 728-730.
97. Mousa, O.; Brater, D.C.; Sunblad, K.J.; Hall, S.D. The interaction of diltiazem with simvastatin. Clin. Pharmacol. Ther., 2000, 67, 267-274.
98. Lilja, J.J.; Kivistö, K.T.; Neuvonen, P.J. Grapefruit juicesimvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther., 1998, 64, 477-483.
99. Blaison, G.; Weber, J.C.; Sachs, D.; Korganow, A.S.; Martin, T.; Kretz, J.G.; Pasquali, J.L. Rhabdomyolyse causée par la simvastatine chez un transplanté cardiaque sous ciclosporine. Rev. Med. Interne., 1992, 13, 61-63.
100. Meier, C.; Stey, C.; Brack, T.; Maggiorini, M.; Risti, B.; Krähenbühl, S. Rhabdomyolyse bei mit Simvastatin und Ciclosporin behandelten Patienten: Rolle der aktivität des Cytochrom-P450-Enzymsystems der Leber. Schweiz Med. Wochenschr., 1995, 125, 1342-1346.
101. Arnadottir, M.; Eriksson, L.O.; Thysell, H.; Karkas, J.D. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron, 1993, 65(3), 410-413.
102. Reaven, P.; Witztum, J.L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann. Intern. Med., 1988, 109, 597-598.
103. Backman, J.T.; Kyrklund, C.; Kivistö, K.T.; Wang, J.S.; Neuvonen, P.J. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin. Pharmacol. Ther., 2000, 68, 122-129.
104. Garnett, W.R. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am. J. Health-Syst Pharm., 1995, 52, 1639-1645.
105. Martin, J.; Krum, H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Safety, 2003, 26, 13-21.
106. Carlucci, G.; Mazzeo, P.; Biordi, L.; Bologna, M. Simultaneous determination of simvastatin and its hydroxy acid form in human plasma by high-performance liquid chromatography with UV detection. J. Pharm. Biomed. Anal., 1992, 10, 693.
107. Ochiai, H.; Uchiyama, N.; Imagaki, K.; Hata, S.; Kamei, T. Determination of simvastatin and its active metabolite in human plasma by column-switching high-performance liquid chromatography with fluorescence detection after derivatization with 1bromoacetylpyrene. J. Chromatogr. B, 1997, 694, 211.
108. Jemal, M.; Ouyang, Z. The need for chromatographic and mass resolution in liquid chromatography/tandem mass spectrometric methods used for quantitation of lactones and corresponding hydroxy acids in biological samples. Rapid Commun. Mass Spectrom., 2000, 14(19), 1757-1765.
109. Jemal, M.; Ouyang, Z.; Powell, M.L. Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. J. Pharm. Biomed. Anal., 2000, 23, 323-340.
110. Zhao, J.J.; Xie, I.H.; Yang, A.Y.; Roadcap, B.A.; Rogers, J.D. Quantitation of simvastatin and its beta-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J. Mass Spectrom., 2000, 35, 1133-1143.
111. Tan, L.; Yang, L.L.; Zhang, X.; Yuan, Y.S.; Ling, S.S. Determination of simvastatin in human plasma by high performance liquid chromatography. Se Pu, 2000, 18(3), 232-234.
112. Zhao, J.J.; Yang, A.Y.; Rogers, J.D. Effects of liquid chromatography mobile phase buffer contents on the ionization and fragmentation of analytes in liquid chromatographic/ionspray tandem mass spectrometric determination. J. Mass Spectrom., 2002, 37, 421-433.
113. Couture, J.; Lévesque, I.M.; Vallée, F. Bioanalysis of Simvastatin and -Hydroxy. Acid Simvastatin in Human EDTA Plasma using LC/MS/MS. http://www.aapsj.org/abstracts/AM_2002/AAPS2002000868.pdf (Assessed May 2010).
114. Srinivasu, M.K.; Narasa R.A.; Reddy, G. O. Determination of lovastatin and simvastatin in pharmaceutical dosage forms by MEKC, J. Pharm. Biomed. Ana., 2002, 29, 715-721.
115. Yang, H.; Feng, Y.; Luan, Y. Determination of Simvastatin in human plasma by liquid chromatography-mass spectrometry. J. Chromatogr., B, 2003, 785(2), 369-375.
116. Gandhimathi, M.; Ravi, T. K.; Varghese, A.; Ninan, A. RP HPLC determination of simvastatin and nicotinic acid in tablets. Indian Drugs, 2003, 40(12), 707-711.
117. Kim, B.C.; Ban, E.; Park, J.S.; Song, Y.K.; Kim, C.K.; Determination of simvastatin in human plasma by column switching HPLC with UV detection. J. Liq. Chromatogr. Relat. Technol., 2004, 27, 3089-3102.
118. Zhang, N.; Yang, A.; Rogers, J.D.; Zhao, J.J. Quantitative analysis of simvastatin and its beta-hydroxy acid in human plasma using automated liquid-liquid extraction based on 96-well plate format and liquid chromatogrphay-tendam mass spectrometry. J. Pharm. Biomed. Anal., 2004, 34, 175-187.
119. Malenovic, A.; Ivanovic, D.; Medenica, M.; Jancic, B.; Markovic, S. Retention modelling in liquid chromatographic separation of simvastatin and six impurities using a microemulsion as eluent. J. Sep. Sci., 2004, 27(13), 1087-1092.
120. Godoy, R.; Godoy, G.; Diego, M.; Gómez, C. Liquid chromatographic assay for fast determination of simvastatin in drug substance, J. Chil. Chem. Soc., 2004, 49(4), 289-289.
121. Srinivasu, M.K.; Narasa, R.A.; Rao, D.S. Determination of lovastatin and simvastatin in pharmaceutical dosage forms by HPLC. Indian Drugs, 2004, 41(3), 156-159.
122. Huai, Q.Y.; Zhao B.; Zuo, Y. M. Preparation and evaluation of an end-capped ptert-butyl-calix[4]arene-bonded-silica stationary phase for reversed-phase high-performance liquid chromatography. Chromatographia, 2004, 59(9-10) 637-645.
123. Yang, A.Y.; Sun, L.; Musson, D.G.; Zhao, J.J. Application of a novel ultra-low elution volume 96-well solid-phase extraction method to the LC/MS/MS determination of simvastatin and simvastatin acid in human plasma. J. Pharm. Biomed. Anal., 2005, 38, 521.
124. Alvarez, L. A.; Valenzuela, C.; Squella, J.A.; Núñez, Vergara, L.J. Stability study of simvastatin under hydrolytic conditions assessed by liquid chromatography. J AOAC Int., 2005, 88(6), 1631-1636.
125. Yang, D.J.; Hwang, L. S. Study on the conversion of three natural statins from lactone forms to their corresponding hydroxy acid forms and their determination in Pu-erh tea. J. Chromatogr. A, 2006, 1119(1-2), 277-284.
126. Malenovic, A.; Medenica, M.; Ivanovic, D.; Jancic, B. Monitoring of Simvastatin Impurities by HPLC with Microemulsion Eluents, Chromatographia Suppl., 2006, 63, S95-S100.
127. Barrett, B.; Huclova, J.; Borek-Dohalsky, V.; Nemec, B.; Jelinek, I. Validated HPLC-MS/MS method for simultaneous determination of simvastatin and simvastatin hydroxy acid in human plasma. J. Pharm. Biomed. Anal., 2006, 41, 517-526.
128. Suchocka, Z.; Swatowska, J.; Pachecka, J.; Suchocki, P. RP-HPLC determination of paraoxonase 3 activity in human blood serum. J. Pharm. Biomed. Anal., 2006, 42, 113-119.
129. Eyad, S.M.; Nameh, A.; Reyad, A.S.; Ali, A. High-performance liquid chromatographic determination of simvastatin in medical drugs, J. Ana. Chem., 2006, 61(1), 63-66.
130. Andelija, M.; Darko, I.; Mirjana, M.; Biljana, J.; Slavko, M. Influence of structural and interfacial properties of microemulsion eluent on chromatographic separation of simvastatin and its impurities. J Chromatogr A., 2006, 1131(1-2), 67-73.
131. Pasha, M. K.; Muzeeb, S. Basha, S.J.S.; Kumar, D.S.; Mullangi, R.; Srinivas, N.R. Analysis of five HMG-CoA reductase inhibitorsatorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies. Biomed. Chromatogr., 2006, 20(3), 282-293.
132. Ozaltin, N.; Ucakturk, E. Simultaneous determination of ezetimibe and simvastatin in pharmaceutical formulations by dual-mode gradient LC. Chromatographia, 2007, 66, S87-S91.
133. Madan, J.; Thakkar, V.; Dwivedi, A.K.; Singh, S. Ion-pairing RPHPLC analytical methods for simultaneous estimation of simvastatin and its hydroxyl acid. J. Sci. Indust. Res., 2007, 66, 371-376.
134. Chaudhari, B.G.; Patel, H.M.; Shah, P.B. Determination of simvastatin, pravastatin sodium and rosuvastatin calcium in tablet dosage forms by HPTLC, Indian J. Pharm. Sci., 2007, 69(1), 130-132.
135. Bharat, G.; Chaudhari, N.; Patel, M.; Shah, P.B. Stabilityindicating reversed-phase liquid chromatographic method for simultaneous determination of simvastatin and ezetimibe from their combination drug products. J. AOAC Internat., 2007, 90(5), 1242-1249.
136. Ashfaq, M.; Khana, I.U.; Qutab, S.S.; Razzaq S.N. HPLC determination of ezetimibe and simvastatin in pharmaceutical formulations. J. Chil. Chem. Soc., 2007, 52, N° 3, 1220-1223.
137. Shivshanker, K.; Sreekanth, N.; Harikrishnan, N.; Roosewelt, C.; Pandiyan, P.S.; Rao, G.S.; Gunasekaran, V. Simultaneous estimation and validation of simvastatin and ezetimibe by HPTLC in pure and pharmaceutical dosage forms. Asian J. Chem., 2007, 19(5), 3627-3632.
138. Shivshanker, K.; Sreekanth, N.; Harikrishnan, N.; Roosewelt, C.; Rao, G.S.; Gunasekaran, V. Validated simultaneous estimation of simvastatin and ezetimibe by RP-HPLC in pure and pharmaceutical dosage form, Asian J. Chem., 2007, 19(6), 4303-4308.
139. Kumar, V.; Shah, R.P.; Singh, S. LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases: Part 1. Separation of active components and classification of their interaction/degradation products. J. Pharm. Biomed. Ana., 2008, 47(3), 508-515.
140. Dhaneshwar, S.S.; Deshpande, P.; Patil, M.; Vadnerkar, G.; Dhaneshwar, S.R. Development and validation of a method for simultaneous densitometric analysis of simvastatin and ezetimibe as the bulk drugs and in the tablet dosage form, Acta Chromatographica, 2008, 20(1), 71-79.
141. Apostolou, C.; Kousoulos, C.; Dotsikas, Y.; Soumelas, G.S.; Kolocouri, F.; Ziaka, A.; Loukas, Y.L. An improved and fully validated LC-MS/MS method for the simultaneous quantification of simvastatin and simvastatin acid in human plasma. J. Pharm. Biomed. Ana., 2008, 46, 771-779.
142. Dixit, R.P.; Barhate, C.R.; Nagarsenker, M.S. Stability-indicating HPTLC method for simultaneous determination of ezetimibe and simvastatin. Chromatographia, 2008, 67, 101-107.
143. Ashfaq, M.; Khan I.U.; Asghar, M.N. Development and validation of liquid chromatographic method for gemfibrozil and simvastatin in binary combination. J. Chil. Chem. Soc., 2008, 53, N° 3, 1617-1619.
144. Yang, G.; Lin, R.; Hu, Z.; Zhang, J.; Han, C.; He, L.; Wang, W. Establishment of the model CD40 cell membrane chromatography and its chromatographic characteristics. Chromatographia, 2008, 67, 829-831.
145. Kumar, R.S.; Santhanakrishnan, M.R.; Nallasivan, P.K.; Nathan, P.S.; Venkatnarayanan, R.; Spectroscopic and HPTLC method for quantification of simvastatin in tablet dosage forms. Asian J. Chem, 2009, 21(9), 6781-6784.
146. Selvan, P.S.; Pal, T.K. Chromatography-tandem mass spectrometry method for the simultaneous quantitation of metoprolol succinate and simvastatin in human plasma. J. Pharm. Biomed. Ana., 2009, 49, 780-785.
147. Ali, H.; Nazzal, S. Development and validation of a reversed-phase HPLC method for the simultaneous analysis of simvastatin and tocotrienols in combined dosage forms. J. Pharm. Biomed. Ana., 2009, 49, 950-956.
148. Nováková, L.; Vl ková, H.; atínsk, D.; Sadílek, P.; Solichová, D.; Bláha, M.; Bláha, V.; Solich, P. Ultra high performance liquid chromatography tandem mass spectrometric detection in clinical analysis of simvastatin and atorvastatin. J. Chromatogr. B, 2009, 877(22), 2093-2103.
149. Hefnawy, M.; Al-Omar, M.; Julkhuf, S. Rapid and sensitive simultaneous determination of ezetimibe and simvastatin from their combination drug products by monolithic silica high-performance liquid chromatographic column, J. Pharm. Biomed. Ana., 2009, 50(3), 527-534.
150. Nováková, L.; Lopéz, S.A.; Solichová, D.; atínsk, D.; Kulichová, B.; Horna, A.; Solich, P. Comparison of UV and charged aerosol detection approach in pharmaceutical analysis of statins. Talanta, 2009, 78(3), 834-839.
151. Kumar, D.A.; Sujan, D.P.; Vijayasree, V.; Rao, J.V.L.N.S. Simultaneous determination of simvastatin and ezetimibe in tablets by HPLC. E-J. Chem., 2009, 6(2), 541-544.
152. Muralidharan, S.; Nagarajan, J.S.K.; Singh, S.; Dubala, A. Bioequivalence study of simvastatin. J. Bioanal. Biomed., 2009, 1, 028-032.
153. Parekh, S.A.; Pudage, A.; Joshi, S.S.; Vaidya, V.V.; Simultaneous determination of simvastatin, simvastatin acid, ramipril and ramiprilate in human plasma by liquid chromatography-tandem mass spectrometry. Asian J. Chem., 2009, 21, 3467-3479.
154. Sankar, D.G.; Kondaveni, R.; Raju, T.V.R.; Krishna, M.V. Gradient stability indicating RP-HPLC method for impurity profiling of simvastatin in tablet dosage forms. Asian J. Chem., 21(6), 4294-4300.
155. Rao, A.L.; Suneetha, D. High performance thin layer chromatographic estimation of simvastatin in bulk and tablet dosage form. Asian J. Chem., 2010, 22(1), 27-30.
156. Piecha, M.; Sarakha, M.; Trebe, P.; Koar, D.; Stability studies of cholesterol lowering statin drugs in aqueous samples using HPLC and LC-MS, Environ. Chem. Letters., 2010, 8(2), 185-191.
157. Dixit, R.P.; Barhate, C.R.; Padhye, S.G.; Viswanathan, C.L.; Nagarsenker, M.S. Stability indicating RP-HPLC method for simultaneous determination of simvastatin and ezetimibe from tablet dosage form. Indian J. Pharm. Sci., 2010, 72(2), 204-210.
158. Zhang, J.; Rodila, R.; Gage, E.; Hautman, M.; Fan, L.; King, L.L.; Wu, H.; El-Shourbagy, T. High-throughput salting-out assisted liquid/liquid extraction with acetonitrile for the simultaneous determination of simvastatin and simvastatin acid in human plasma with liquid chromatography. Analytical Chimica. Acta, 2010, 661(2), 167-172.
159. Krishna, S.R.; Deshpande, G.R.; Rao, B.M.; Rao, N.S. Stabilityindicating RP-LC method for the determination of related substances in simvastatin. J. Chem. Pharm. Res., 2010, 2(1), 91-99.
160. Sama, J.R.; Kalakuntla, R.R.; Rao, V.S.N.; Reddanna, P.; Simultaneous estimation of simvastatin and ezetimibe in pharmaceutical formulations by RP-HPLC method. J. Pharm. Sci. Res., 2010, 2(2), 82-89.
161. Rahman, M.U.; Parveen, G.; Nyola, N.K.; Khan, S.; Talegaonkar, S.; Yar, M.S.; Khar, R.K. Simultaneous estimation of simvastatin and ezetimibe in pharmaceutical tablet dosage forms by RP-HPLC: A review. Int. J. Pharm. Res. Dev.-Online, 2010, 2(9), 008.
162. Markman, B.E.O.; Rosa, P.C.P.; Koschtschak, M.R.W.; Assessment of the quality of simvastatin capsules from compounding pharmacies. Rev Saúde Pública, 2010, 44(6), 1-7.
163. Nagaraju, P.; Vishnu vardhan, Z. A Validated reverse phase HPLC method for the simultaneous estimation of simvastatin and ezetimibe in pharmaceutical dosage forms. J. Global Pharma. Techno., 2010, 2(4), 113-117.
164. Tiwari, P.K.; Sathe, P. Development and validation of HPTLC method for niacin and simvastatin in binary combination. Adv. Biosci. Biotechno., 2010, 1, 131-135.
165. Dami, M.; Nigovi, B.; Fast analysis of statins in pharmaceuticals by MEKC. Chromatographia, 2010, 71(3-4), 233-240.
166. Rathinaraj, B.S.; Rajamanickam, V.; Rajveer, C.; Kumaraswamy, D.; Banglae, G.S.; Shinde, G.V. Development and validation of HPTLC method for the estimation of simvastatin and ezetimibe. J. Pharm. Sci. Techno., 2010, 2(8), 288-292.
167. Narkhede, S.P.; Vidyasagar, G.; Jadhav, A.G.; Narkhede, S.B.; Bendale, A.R. Development and validation of reverse phase HPLC method for determination of simvastatin and ezetimibe in tablet dosage form. Der Pharmacia Sinica, 2011, 2(1), 49-56.
168. Ding, M.J.; Yuan, L.H.; Li, Y.; Wang, S.; Wu, X.L.; Liu, J.; Ma, K.F.; Fan, H.W.; Lu, Z.Y.; Xu, H.J.; Zhou, X.M. Pharmacokinetics and bioequivalence study of simvastatin orally disintegrating tablets in chinese healthy volunteers by LC-ESI-MS/MS. J. Bioequiv. Availab., 2011, 3, 032-037.
169. Takano, T.; Abe, S.; Hata, S. A selected ion monitoring method for quantifying simvastatin and its acid form in human plasma, using the ferroceneboronate derivative. Biolog. Mass Spectro., 1990, 19(9), 577-581.
170. Morris, M.J.; Gilbert, J.D.; Hsieh, J.Y.K.; Matuszewski, B.K.; Ramjit, H.G.; Bayne W.F. Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. Biolog. Mass Spectro., 1993, 22(1), 1-8.
171. Wang, L.; Asgharnejad, M. Second-derivative UV spectrometric determination of simvastatin in its tablet dosage form. J. Pharm. Biomed. Ana., 2000, 21(6), 1243-1248.
172. Erk, N. Rapid spectrophotometric method for quantitative determination of simvastatin and fluvastatin in human serum and pharmaceutical formulations. Pharmazie, 2002, 57(12), 817-819.
173. Liu, L.; Zhang, R.; Zhao, J.J.; Rogers, J.D.; Hsieh, J.Y.K.; Fang, W.; Matuszewski, B.K.; Dobrinska, M.R. Determination of simvastatin-derived HMG-CoA reductase inhibitors in biomatrices using an automated enzyme inhibition assay with radioactivity detection. J. Pharm. Biomed. Ana., 2003, 32, 107-123.
174. Lovric, S.K.; Nigovi, B. Electrochemical characterization of simvastatin by abrasive stripping and square-wave voltammetry. J. Electroana. Chem., 2006, 593, 125-130.
175. Coruh, Ö.; Özkan, S.A. Determination of the antihyperlipidemic simvastatin by various voltammetric techniques in tablets and serum samples. Pharmazie, 2006, 61(4), 285-290.
176. Arayne, M.S.; Sultana, N.; Hussain, F.; Ali, S.A. Validated spectrophotometric method for quantitative determination of simvastatin in pharmaceutical formulations and human serum. J. Ana. Chem., 2007, 62(6), 536-541.
177. Rajput, S.J.; Raj, H.A. Simultaneous spectroscopic estimation of ezetimibe and simvastatin in tablet dosage forms, Indian J. Pharm. Sci., 2007, 69(6), 759-762.
178. Basavaiah, K.; Tharpa, K. The development and validation of visible spectrophotometric methods for simvastatin determination in pure and the tablet dosage forms. Chem. Ind. Chem. Engg. Quart., 2008, 14(3), 205-210.
179. Basavaiah, K.; Devi, O.Z. Cerimetric determination of simvastatin in pharmaceuticals based on redox and complex formation reactions. Ecletica. Quimica., 2008, 33(2), 21-28.
180. Nigovic, B.; Lovric, S.K.; Devcic, D. Rapid voltammetric identification and determination of simvastatin at trace levels in pharmaceuticals and biological fluid. Croatica Chemica Acta, 2008, 81(3), 453-459.
181. Karajgi, S.R.; Simpi, C.C. Simultaneous estimation of simvastatin and ezetimibe in tablet formulations. Asian J. Chem., 2008, 20(1), 826-828.
182. Tharpa, K.; Basavaiah, K. Bromatometric assay of simvastatin in pharmaceuticals. J. Ana. Chem., 2009, 64(11), 1193-1198.
183. Jain, N.; Jain, R.; Swami, H.; Pandey S.; Jain, D.K. Spectrophotometric method for simultaneous estimation of simvastatin and ezetimibe in bulk drug and its combined dosage form. Internat. J. Pharmacy Pharm. Sci., 2009, 1(1), 170-175.
184. Balaji, S.; Sunitha, A. Development and validation of spectrophotometeric method for simultaneous determination of simvastatin and ezetimibe in tablet formulations. Pak. J. Pharm. Sci., 2010, 23(4), 375-378.
185. Sharaf El-Din, M.M.; Attia, K.A.; Nassar, M.W.; Kaddah, M.M.; Colorimetric determination of simvastatin and lovastatin in pure form and in pharmaceutical formulations. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2010, 76(3-4), 423-428.
186. Joshi, H.V.; Patel, J.K.; Kothapalli, L.; Simultaneous derivative and multicomponent spectrophotometric determination of simvastatin and ezetimibe in tablets. Der Pharma Chemica, 2010, 2(2), 152-156.
187. Farouk, M.; Abdel-Aziz, O.; Nagi, R.; Abdel-Fattah, L. Validated spectrophotometric methods for determination of some antihyperlipidemic used drugs. J. Biomed. Sci. Res., 2010, 2(3), 202-211.
188. Eman, Y.Z.; Frag, Gehad, G.; Mohamed, M.; Gaber, H. Sensitive extractive spectrophotometric method for the determination of some statin drugs in pharmaceutical preparations. Insight Pharma. Sci., 2011, 1(4), 39-46.
189. Tan, L.; Yang, L.L.; Zhang, X.; Ling, S.S. The pharmacokinetics and relative bioavailability of simvastatin capsules in healthy volunteers. The Chinese J. Clinical Pharmacol., 2000, 01-01.
190. Zhang, X.H.; Zhang, C.H.; Ling, G.Y. Pharmacokinetic and relative bioavailability of simvastatin tablet in healthy volunteers. Chinese J. Hospital Pharmacy., 2004, 4-5.
191. Wang, J.; Liu, S.; Ju, W. Determination of simvastatin in human plasma by LC/MS/MS. China Pharmacy, 2007, 5-5.
192. Yang, X.; Zhang, L.L.; Qiangni, G.P.; Zeng, F. Determination simvastatin in plasma by LC/MS/MS and pharmacokinetic studies of simvastatin tablet in healthy volunteers. China Pharmacist, 2007, 12-12.
193. Yang Y.; Di, X.; Li, G.; Xu, X.; Liu, J. Pharmacokinetics and relative bioavailability of simvastatin tablets in healthy volunteers. Medical J. National Defending Forces North China, 2008, 3-3.
194. Zhang, Y.; Yang, H.; Zhao, X. Determination of simvastatin in human plasma by LC-MS/MS[J]; West China J. Pharm. Sci., 2008, 3-3.
195. Liu, P.; Li, J.; Cao, J.; Luo, X.; Wan, X.; Li, Y. Pharmacokinetics and bioequivalence of Simvastatin tablets in healthy volunteers. China Medical Herald, 2009, 11-11.
196. Zhao, L.; Xu, D.; Wang, Y. Study on pharmacokinetics and bioequivalence of simvastatin sustained release tablets in beagle dogs. China Pharmacy, 2010, 25-25.